ALK and angioimmunoblastic T-cell lymphoma: Most patients treated with A + CHP had sALCL (ALK+ and ALK−, 51%), PTCL-NOS (30%), or AITL (12%); in contrast, most patients treated with CHOP had PTCL-NOS (51%), AITL (19%), sALCL (ALK + and ALK–, 10%), or mature T/NK-cell lymphoma (8%).